Bavarian Nordic upgraded its full-year 2026 financial guidance due to stronger-than-expected sales in its Travel Health segment, particularly rabies vaccines in the U.S. Total revenue is now expected to reach approximately DKK 6,100 million, up from previous guidance of DKK 5,700 million, with an EBITDA margin forecast raised to about 32% from 30%. The increase is driven by higher demand for rabies vaccines amid rising animal rabies cases, while other revenue streams remain stable. This positive outlook reflects the company's strong market position and demand in travel and public health vaccines.
Bavarian Nordic's upgraded 2026 financial guidance follows strong Travel Health segment sales. For readers following the health sector, here is Pluang's market snapshot as of Oct 08, 2026 12:11 WIB: of 100 priced US health stocks, 44 rose and 52 fell. Notable movers include AHCO at USD 5.91 (+2.43%), AMLX at USD 27.36 (-2.43%), and RMD at USD 225.68 (+2.26%).
FLSmidth secured a DKK 360 million contract to supply advanced crushing and grinding equipment for a copper mine expansion in Northern Chile. The order includes the world's largest gyratory crusher, a large SAG mill, and three ball mills, with instal...
On October 8, 2026, Michelin repurchased 202,417 of its own ordinary shares at a weighted average price of €32.33 per share through over-the-counter transactions. The shares bought back are intended for cancellation, which can reduce the total number...
On October 8, 2026, Michelin executed a share buyback, purchasing 202,417 ordinary shares at a weighted average price of €32.33 per share. The shares were acquired through over-the-counter transactions involving several financial institutions and are...
FORVIA HELLA has secured two significant series orders for its EnergyCore solutions, including its first 3-in-1 high-voltage battery management system and a 48-volt PowerPack. These integrated systems reduce vehicle cost, complexity, weight, and spac...
Bavarian Nordic A/S has upgraded its financial outlook for 2026 due to stronger-than-expected sales in its Travel Health segment, particularly driven by increased demand for rabies vaccines in the U.S. amid rising rabies exposure. The company now exp...
